MX2022007680A - Nanoparticulas lipidicas para administracion de acidos nucleicos. - Google Patents
Nanoparticulas lipidicas para administracion de acidos nucleicos.Info
- Publication number
- MX2022007680A MX2022007680A MX2022007680A MX2022007680A MX2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A MX 2022007680 A MX2022007680 A MX 2022007680A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery
- nucleic acids
- lipid nanoparticles
- cationic lipids
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019086825 | 2019-12-20 | ||
| PCT/EP2020/087254 WO2021123332A1 (en) | 2019-12-20 | 2020-12-18 | Lipid nanoparticles for delivery of nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007680A true MX2022007680A (es) | 2022-09-26 |
Family
ID=69156396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007680A MX2022007680A (es) | 2019-12-20 | 2020-12-18 | Nanoparticulas lipidicas para administracion de acidos nucleicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12589078B2 (enExample) |
| EP (1) | EP4076647A1 (enExample) |
| JP (2) | JP7846621B2 (enExample) |
| KR (1) | KR20220121246A (enExample) |
| CN (1) | CN114901360A (enExample) |
| AU (1) | AU2020407285A1 (enExample) |
| BR (1) | BR112022011803A2 (enExample) |
| CA (1) | CA3162019A1 (enExample) |
| IL (1) | IL293890A (enExample) |
| MX (1) | MX2022007680A (enExample) |
| WO (1) | WO2021123332A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| CA3102135A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| CA3162019A1 (en) | 2019-12-20 | 2021-06-24 | Gemma NAVARRO | Lipid nanoparticles for delivery of nucleic acids |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN115968280A (zh) * | 2020-05-18 | 2023-04-14 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| IL309502A (en) * | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| KR20240099256A (ko) * | 2021-10-08 | 2024-06-28 | 화이자 인코포레이티드 | 면역원성 lnp 조성물 및 이의 방법 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| WO2023076704A1 (en) * | 2021-10-31 | 2023-05-04 | CELESTIAL THERAPEUTICS Inc. | SELECTIVE AGONISM OF SPECIFIC PATTERN RECOGNITION RECEPTORS IN mRNA CONSTRUCTS FOR SAFE, EFFECTIVE AND DURABLE VACCINES |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| FR3129833B1 (fr) | 2021-12-03 | 2024-09-06 | Univ Claude Bernard Lyon | Nanoparticules pour la liberation d’acides nucleiques |
| CA3242439A1 (en) * | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
| EP4448002A1 (en) * | 2021-12-17 | 2024-10-23 | Pfizer Inc. | Polynucleotide compositions and uses thereof |
| WO2023121964A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| CA3143650A1 (en) * | 2021-12-22 | 2023-06-22 | Providence Therapeutics Holdings Inc. | Lipids and compositions thereof |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023164155A2 (en) * | 2022-02-25 | 2023-08-31 | Cureport Inc. | Lipid nanoparticle compositions and methods of use thereof |
| KR102560772B1 (ko) | 2022-03-21 | 2023-07-28 | 주식회사 메디치바이오 | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 |
| WO2024226031A1 (en) * | 2023-04-22 | 2024-10-31 | Malarvx Inc. | Compositions, devices, systems and methods relating to vaccination and sterile protection against malaria |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| EP4342460A1 (en) | 2022-09-21 | 2024-03-27 | NovoArc GmbH | Lipid nanoparticle with nucleic acid cargo |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| CN120475962A (zh) * | 2022-11-11 | 2025-08-12 | 卡卢萨生物有限公司 | 包含聚肌氨酸脂质偶联物的颗粒组合物 |
| CN116712536B (zh) * | 2022-11-18 | 2025-06-06 | 上海复诺健生物科技有限公司 | 针对痘病毒的信使核糖核酸疫苗 |
| US20260216313A1 (en) * | 2022-12-23 | 2026-07-30 | Pfizer Inc. | Lipid particle compositions and methods of use thereof |
| JP2026500600A (ja) | 2022-12-29 | 2026-01-08 | 仁景（▲蘇▼州）生物科技有限公司 | Ｈｐｖ感染関連疾患を予防又は治療するためのポリヌクレオチド分子 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| KR20240159310A (ko) | 2023-04-28 | 2024-11-05 | 주식회사 메디치바이오 | 신규한 이온화지질을 이용한 지질나노입자 조성물 |
| CN116617414B (zh) * | 2023-03-31 | 2024-04-05 | 中国农业大学 | 一种脂质体及其制备方法和应用 |
| CN116536355B (zh) * | 2023-03-31 | 2023-10-20 | 中国农业大学 | 一种crRNA转录载体、CRISPR/Cas13d体系和RNA投送体系和应用 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| KR20260018077A (ko) | 2023-05-26 | 2026-02-06 | 큐어백 에스이 | 암 항원 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
| EP4731655A1 (en) | 2023-06-23 | 2026-04-29 | CureVac SE | Nucleic acid encoded antibodies |
| KR20260074932A (ko) * | 2023-06-30 | 2026-05-27 | 세퀴러스 인코포레이티드 | 복합 rna 백신 |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025034965A1 (en) * | 2023-08-09 | 2025-02-13 | Board Of Regents, The University Of Texas System | Targeted therapeutic delivery of lipid nanoparticles |
| EP4761761A1 (en) | 2023-08-16 | 2026-06-24 | CureVac SE | Rna conjugates |
| KR20260065891A (ko) | 2023-09-01 | 2026-05-11 | 노보아크 게엠베하 | 핵산 카고 및 이온화가능한 지질을 갖는 지질 나노입자 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025124586A1 (zh) | 2023-12-15 | 2025-06-19 | 厦门赛诺邦格生物科技股份有限公司 | 一种含二硫键的可降解阳离子脂质及其应用 |
| WO2025130965A1 (en) * | 2023-12-22 | 2025-06-26 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Uses of lipid nanoparticle compositions |
| WO2025150516A1 (ja) * | 2024-01-12 | 2025-07-17 | 日油株式会社 | 核酸内封脂質ナノ粒子を含む凍結組成物 |
| CN120647684A (zh) * | 2024-03-13 | 2025-09-16 | 清华大学 | 含有生育酚结构的辅助脂质分子、包含其的脂质纳米颗粒及其用途 |
| WO2025219570A1 (en) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition for inhibiting protein translocation and methods using the same |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
| WO2026006277A2 (en) | 2024-06-25 | 2026-01-02 | Massachusetts Institute Of Technology | Viral subunit vaccines |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| ATE492644T1 (de) | 1999-09-09 | 2011-01-15 | Curevac Gmbh | Transfer von mrna unter verwendung von polykationischen verbindungen |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5721441B2 (ja) | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ | 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体 |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2391343B1 (en) | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| WO2013073480A1 (ja) | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| ES2660129T3 (es) | 2012-03-27 | 2018-03-20 | Curevac Ag | Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP |
| WO2013143698A1 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| EP2854857B1 (en) | 2012-05-25 | 2018-11-28 | CureVac AG | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| AU2014310932B2 (en) | 2013-08-21 | 2019-06-06 | CureVac SE | Composition and vaccine for treating lung cancer |
| BR112016000889A2 (pt) | 2013-08-21 | 2017-12-12 | Curevac Ag | composição e vacina para tratamento de câncer de próstata |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| AU2014375402B2 (en) | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| SG11201608605QA (en) | 2014-06-10 | 2016-12-29 | Curevac Ag | Methods and means for enhancing rna production |
| KR102559979B1 (ko) | 2014-06-24 | 2023-07-25 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| EP4023755B1 (en) | 2014-12-12 | 2023-04-26 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| BR112017009835A2 (pt) | 2014-12-30 | 2017-12-26 | Curevac Ag | moléculas de ácido nucleico artificiais |
| WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| JP6640750B2 (ja) * | 2015-01-30 | 2020-02-05 | 日油株式会社 | カチオン性脂質 |
| EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| US10780054B2 (en) | 2015-04-17 | 2020-09-22 | Curevac Real Estate Gmbh | Lyophilization of RNA |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| WO2016174271A1 (en) | 2015-04-30 | 2016-11-03 | Curevac Ag | Immobilized poly(n)polymerase |
| EP3289077B1 (en) | 2015-04-30 | 2020-04-15 | CureVac AG | Method for in vitro transcription using an immobilized restriction enzyme |
| WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
| DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
| EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| DK3303583T3 (da) | 2015-05-29 | 2020-07-13 | Curevac Real Estate Gmbh | Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering |
| EP3310384A1 (en) | 2015-06-17 | 2018-04-25 | CureVac AG | Vaccine composition |
| EP4239080A3 (en) | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
| US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
| WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
| EP3699288A1 (en) | 2015-08-07 | 2020-08-26 | CureVac AG | Process for the in vivo production of rna in a host cell |
| WO2017025447A1 (en) | 2015-08-10 | 2017-02-16 | Curevac Ag | Method of increasing the replication of a circular dna molecule |
| US12258567B2 (en) | 2015-08-28 | 2025-03-25 | CureVac SE | Artificial nucleic acid molecules |
| US20190054112A1 (en) | 2015-09-18 | 2019-02-21 | Moderna Therapeutics, Inc. | Polynucleotide formulations for use in the treatment of renal diseases |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| US11395798B2 (en) * | 2015-10-08 | 2022-07-26 | Nof Corporation | O/W type emulsion |
| WO2017064146A1 (en) | 2015-10-12 | 2017-04-20 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| JP2018530587A (ja) | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
| MA46023A (fr) | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| WO2017108087A1 (en) | 2015-12-21 | 2017-06-29 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| US20190049414A1 (en) | 2016-02-15 | 2019-02-14 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
| WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| WO2017162297A1 (en) | 2016-03-24 | 2017-09-28 | Curevac Ag | Immobilized inorganic pyrophosphatase (ppase) |
| EP4487869A3 (en) | 2016-04-22 | 2025-07-30 | CureVac SE | Rna encoding a tumor antigen |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| EP4631970A3 (en) | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| EP4233898A3 (en) | 2016-05-04 | 2023-11-01 | CureVac SE | Influenza mrna vaccines |
| WO2017203008A1 (en) | 2016-05-25 | 2017-11-30 | Curevac Ag | Novel biomarkers |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
| WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| US20190336611A1 (en) | 2016-06-09 | 2019-11-07 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| CN109715205A (zh) | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| KR20190093816A (ko) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
| WO2018104538A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rna for treatment or prophylaxis of a liver disease |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| WO2018126084A1 (en) | 2016-12-30 | 2018-07-05 | Phaserx, Inc. | Branched peg molecules and related compositions and methods |
| CA3050614A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| US11015204B2 (en) | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| WO2018237369A2 (en) | 2017-06-23 | 2018-12-27 | Vical Incorporated | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
| JP7722629B2 (ja) | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| BR112020004351A2 (pt) | 2017-10-19 | 2020-09-08 | Curevac Ag | moléculas de ácido nucleico artificial |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| CN111971066B (zh) * | 2018-01-18 | 2025-03-11 | 伊泽阿恩埃免疫疗法股份有限公司 | 脂质纳米颗粒 |
| CA3094057C (en) * | 2018-03-27 | 2025-04-08 | Nof Corporation | CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS |
| EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| US12076439B2 (en) | 2018-05-24 | 2024-09-03 | Translate Bio, Inc. | Thioester cationic lipids |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| CA3102135A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| CA3118142A1 (en) | 2018-11-02 | 2020-05-07 | Genevant Sciences Gmbh | Therapeutic methods |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| AU2019410737A1 (en) | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| EP3920950A1 (en) | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| WO2020219941A1 (en) | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
| CA3162019A1 (en) | 2019-12-20 | 2021-06-24 | Gemma NAVARRO | Lipid nanoparticles for delivery of nucleic acids |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| US20240288407A1 (en) | 2020-06-15 | 2024-08-29 | CureVac SE | Analysis of nucleic acid mixtures |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
-
2020
- 2020-12-18 CA CA3162019A patent/CA3162019A1/en active Pending
- 2020-12-18 JP JP2022537725A patent/JP7846621B2/ja active Active
- 2020-12-18 WO PCT/EP2020/087254 patent/WO2021123332A1/en not_active Ceased
- 2020-12-18 AU AU2020407285A patent/AU2020407285A1/en active Pending
- 2020-12-18 IL IL293890A patent/IL293890A/en unknown
- 2020-12-18 BR BR112022011803A patent/BR112022011803A2/pt unknown
- 2020-12-18 US US17/757,736 patent/US12589078B2/en active Active
- 2020-12-18 EP EP20838055.0A patent/EP4076647A1/en active Pending
- 2020-12-18 MX MX2022007680A patent/MX2022007680A/es unknown
- 2020-12-18 CN CN202080088512.1A patent/CN114901360A/zh active Pending
- 2020-12-18 KR KR1020227025095A patent/KR20220121246A/ko active Pending
-
2025
- 2025-12-25 JP JP2025281854A patent/JP2026065025A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230090515A1 (en) | 2023-03-23 |
| WO2021123332A1 (en) | 2021-06-24 |
| EP4076647A1 (en) | 2022-10-26 |
| BR112022011803A2 (pt) | 2022-08-30 |
| JP7846621B2 (ja) | 2026-04-15 |
| AU2020407285A1 (en) | 2022-08-11 |
| JP2023507465A (ja) | 2023-02-22 |
| US12589078B2 (en) | 2026-03-31 |
| JP2026065025A (ja) | 2026-04-14 |
| KR20220121246A (ko) | 2022-08-31 |
| CA3162019A1 (en) | 2021-06-24 |
| CN114901360A (zh) | 2022-08-12 |
| IL293890A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022011803A2 (pt) | Nanopartículas de lipídio para entrega de ácidos nucleicos | |
| MX2024002726A (es) | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. | |
| WO2022120388A3 (en) | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | |
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| ES3065955T3 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| WO2020051220A8 (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| EP4036079A3 (en) | Compounds and compositions for intracellular delivery of agents | |
| MX2025000703A (es) | Arn guia modificados | |
| MX2024000327A (es) | Composiciones y metodos para la administracion de arn mensajero. | |
| EP4286012A3 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| CA2868034C (en) | Ionizable cationic lipids | |
| EP4614148A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| WO2015011633A8 (en) | Compositions and methods for delivering messenger rna | |
| MX2019011004A (es) | Compuestos y composiciones para la administracion intracelular de agentes terapeuticos. | |
| NZ700075A (en) | Trialkyl cationic lipids and methods of use thereof | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| IN2014MN01886A (enExample) | ||
| BR112014001907A2 (pt) | produção de dha e outros lc-pufas em plantas | |
| WO2011149733A3 (en) | Novel amino alcohol cationic lipids for oligonucleotide delivery | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| EP4481047A3 (en) | Biodegradable lipids for the delivery of active agents | |
| EP4241767A3 (en) | Novel lipids and compositions for the delivery of therapeutics | |
| WO2016154127A3 (en) | Compositions and methods for treating hypertriglyceridemia |